MedTrace Logo

Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers

NCT02992236 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-08-09

Study results available
· View outcomes & findings →

Summary

Analysis of the effect of the NO-Synthase inhibitor VAS203 (6 hours infusion of 10 mg/kg) on renal function and perfusion in 16 healthy subjects.

Conditions

  • Renal Function Impairment in Healthy Volunteers

Interventions

DRUG

VAS203

Infusion of NO-Synthase inhibitor VAS203

DRUG

Saline

Infusion of saline

Sponsors & Collaborators

  • Winicker Norimed GmbH

    collaborator INDUSTRY

  • veriNOS operations GmbH

    lead INDUSTRY

Principal Investigators

  • Roland E Schmieder, Prof. Dr. · Universitätsklinik Erlangen

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-05-31
Completion
2016-11-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02992236 on ClinicalTrials.gov